Controversies  ||| S:0 E:14 ||| NNS
around  ||| S:14 E:21 ||| IN
the  ||| S:21 E:25 ||| DT
use  ||| S:25 E:29 ||| NN
of  ||| S:29 E:32 ||| IN
monoclonal  ||| S:32 E:43 ||| JJ
antibodies  ||| S:43 E:54 ||| NNS
in  ||| S:54 E:57 ||| IN
the  ||| S:57 E:61 ||| DT
treatment  ||| S:61 E:71 ||| NN
of  ||| S:71 E:74 ||| IN
advanced  ||| S:74 E:83 ||| JJ
non-small  ||| S:83 E:93 ||| JJ
cell  ||| S:93 E:98 ||| NN
lung  ||| S:98 E:103 ||| NN
cancer  ||| S:103 E:110 ||| NN
First  ||| S:110 E:116 ||| JJ
line  ||| S:116 E:121 ||| NN
combination  ||| S:121 E:133 ||| NN
chemotherapy  ||| S:133 E:146 ||| NNS
( ||| S:146 E:147 ||| -LRB-
CT ||| S:147 E:149 ||| NNP
)  ||| S:149 E:151 ||| -RRB-
using  ||| S:151 E:157 ||| VBG
platinum-based  ||| S:157 E:172 ||| JJ
doublets  ||| S:172 E:181 ||| NN
is  ||| S:181 E:184 ||| VBZ
established  ||| S:184 E:196 ||| VBN
as  ||| S:196 E:199 ||| IN
a  ||| S:199 E:201 ||| DT
standard  ||| S:201 E:210 ||| NN
of  ||| S:210 E:213 ||| IN
care  ||| S:213 E:218 ||| NN
for  ||| S:218 E:222 ||| IN
advanced  ||| S:222 E:231 ||| JJ
non-small  ||| S:231 E:241 ||| JJ
cell  ||| S:241 E:246 ||| NN
lung  ||| S:246 E:251 ||| NN
cancer  ||| S:251 E:258 ||| NN
( ||| S:258 E:259 ||| -LRB-
NSCLC ||| S:259 E:264 ||| NNP
) ||| S:264 E:265 ||| -RRB-
.  ||| S:265 E:267 ||| .
Nevertheless ||| S:267 E:279 ||| RB
,  ||| S:279 E:281 ||| ,
no  ||| S:281 E:284 ||| DT
significant  ||| S:284 E:296 ||| JJ
advances  ||| S:296 E:305 ||| NNS
have  ||| S:305 E:310 ||| VBP
been  ||| S:310 E:315 ||| VBN
recorded  ||| S:315 E:324 ||| VBN
during  ||| S:324 E:331 ||| IN
the  ||| S:331 E:335 ||| DT
last  ||| S:335 E:340 ||| JJ
years  ||| S:340 E:346 ||| NNS
in  ||| S:346 E:349 ||| IN
this  ||| S:349 E:354 ||| DT
field ||| S:354 E:359 ||| NN
.  ||| S:359 E:361 ||| .
Therefore ||| S:361 E:370 ||| RB
,  ||| S:370 E:372 ||| ,
there  ||| S:372 E:378 ||| EX
is  ||| S:378 E:381 ||| VBZ
a  ||| S:381 E:383 ||| DT
wide  ||| S:383 E:388 ||| JJ
consensus  ||| S:388 E:398 ||| NN
among  ||| S:398 E:404 ||| IN
physicians  ||| S:404 E:415 ||| NNS
that  ||| S:415 E:420 ||| IN
a  ||| S:420 E:422 ||| DT
plateau  ||| S:422 E:430 ||| NN
has  ||| S:430 E:434 ||| VBZ
already  ||| S:434 E:442 ||| RB
been  ||| S:442 E:447 ||| VBN
reached  ||| S:447 E:455 ||| VBN
with  ||| S:455 E:460 ||| IN
this  ||| S:460 E:465 ||| DT
strategy ||| S:465 E:473 ||| NN
.  ||| S:473 E:475 ||| .
Targeted  ||| S:475 E:484 ||| JJ
therapy  ||| S:484 E:492 ||| NN
using  ||| S:492 E:498 ||| VBG
tyrosine-kinase  ||| S:498 E:514 ||| JJ
inhibitors  ||| S:514 E:525 ||| NNS
( ||| S:525 E:526 ||| -LRB-
TKIs ||| S:526 E:530 ||| NNP
)  ||| S:530 E:532 ||| -RRB-
and  ||| S:532 E:536 ||| CC
monoclonal  ||| S:536 E:547 ||| JJ
antibodies  ||| S:547 E:558 ||| NNS
emerged  ||| S:558 E:566 ||| VBD
as  ||| S:566 E:569 ||| IN
a  ||| S:569 E:571 ||| DT
new  ||| S:571 E:575 ||| JJ
field  ||| S:575 E:581 ||| NN
of  ||| S:581 E:584 ||| IN
development  ||| S:584 E:596 ||| NN
in  ||| S:596 E:599 ||| IN
the  ||| S:599 E:603 ||| DT
NSCLC  ||| S:603 E:609 ||| NNP
therapeutics ||| S:609 E:621 ||| NN
.  ||| S:621 E:623 ||| .
Recently ||| S:623 E:631 ||| RB
,  ||| S:631 E:633 ||| ,
the  ||| S:633 E:637 ||| DT
results  ||| S:637 E:645 ||| NNS
of  ||| S:645 E:648 ||| IN
the  ||| S:648 E:652 ||| DT
phase  ||| S:652 E:658 ||| NN
III  ||| S:658 E:662 ||| NNP
trials  ||| S:662 E:669 ||| NNS
testing  ||| S:669 E:677 ||| VBG
antibodies  ||| S:677 E:688 ||| NNS
against  ||| S:688 E:696 ||| IN
vascular  ||| S:696 E:705 ||| JJ
endothelial  ||| S:705 E:717 ||| JJ
growth  ||| S:717 E:724 ||| NN
factor-VEGF  ||| S:724 E:736 ||| NNS
( ||| S:736 E:737 ||| -LRB-
bevacizumab ||| S:737 E:748 ||| LS
)  ||| S:748 E:750 ||| -RRB-
and  ||| S:750 E:754 ||| CC
epidermal  ||| S:754 E:764 ||| JJ
growth  ||| S:764 E:771 ||| NN
factor  ||| S:771 E:778 ||| NN
receptor-EGFR  ||| S:778 E:792 ||| NNS
( ||| S:792 E:793 ||| -LRB-
cetuximab ||| S:793 E:802 ||| LS
)  ||| S:802 E:804 ||| -RRB-
challenged  ||| S:804 E:815 ||| VBD
the  ||| S:815 E:819 ||| DT
paradigm  ||| S:819 E:828 ||| NN
of  ||| S:828 E:831 ||| IN
the  ||| S:831 E:835 ||| DT
platinum  ||| S:835 E:844 ||| NN
doublets  ||| S:844 E:853 ||| NN
as  ||| S:853 E:856 ||| IN
a  ||| S:856 E:858 ||| DT
gold  ||| S:858 E:863 ||| NN
standard  ||| S:863 E:872 ||| NN
in  ||| S:872 E:875 ||| IN
advanced  ||| S:875 E:884 ||| JJ
NSCLC ||| S:884 E:889 ||| NNP
.  ||| S:889 E:891 ||| .
Their  ||| S:891 E:897 ||| PRP$
appearance  ||| S:897 E:908 ||| NN
was  ||| S:908 E:912 ||| VBD
enthusiastically  ||| S:912 E:929 ||| RB
commended  ||| S:929 E:939 ||| VB
both  ||| S:939 E:944 ||| DT
by  ||| S:944 E:947 ||| IN
patients  ||| S:947 E:956 ||| NNS
and  ||| S:956 E:960 ||| CC
the  ||| S:960 E:964 ||| DT
oncological  ||| S:964 E:976 ||| JJ
community ||| S:976 E:985 ||| NN
.  ||| S:985 E:987 ||| .
However ||| S:987 E:994 ||| RB
,  ||| S:994 E:996 ||| ,
all  ||| S:996 E:1000 ||| DT
medical  ||| S:1000 E:1008 ||| JJ
oncologists  ||| S:1008 E:1020 ||| NNS
have  ||| S:1020 E:1025 ||| VBP
the  ||| S:1025 E:1029 ||| DT
responsibility  ||| S:1029 E:1044 ||| NN
to  ||| S:1044 E:1047 ||| TO
carefully  ||| S:1047 E:1057 ||| RB
analyze  ||| S:1057 E:1065 ||| VB
the  ||| S:1065 E:1069 ||| DT
real  ||| S:1069 E:1074 ||| JJ
benefits  ||| S:1074 E:1083 ||| NNS
of  ||| S:1083 E:1086 ||| IN
these  ||| S:1086 E:1092 ||| DT
new  ||| S:1092 E:1096 ||| JJ
agents ||| S:1096 E:1102 ||| NNS
,  ||| S:1102 E:1104 ||| ,
to  ||| S:1104 E:1107 ||| TO
balance  ||| S:1107 E:1115 ||| VB
the  ||| S:1115 E:1119 ||| DT
advantages  ||| S:1119 E:1130 ||| NNS
against  ||| S:1130 E:1138 ||| IN
the  ||| S:1138 E:1142 ||| DT
implicit  ||| S:1142 E:1151 ||| JJ
risks  ||| S:1151 E:1157 ||| NNS
of  ||| S:1157 E:1160 ||| IN
therapy  ||| S:1160 E:1168 ||| NN
and  ||| S:1168 E:1172 ||| CC
to  ||| S:1172 E:1175 ||| TO
make  ||| S:1175 E:1180 ||| VB
the  ||| S:1180 E:1184 ||| DT
decision  ||| S:1184 E:1193 ||| NN
having  ||| S:1193 E:1200 ||| VBG
in  ||| S:1200 E:1203 ||| IN
mind  ||| S:1203 E:1208 ||| NN
the  ||| S:1208 E:1212 ||| DT
best  ||| S:1212 E:1217 ||| JJS
interest  ||| S:1217 E:1226 ||| NN
of  ||| S:1226 E:1229 ||| IN
their  ||| S:1229 E:1235 ||| PRP$
patients ||| S:1235 E:1243 ||| NNS
.  ||| S:1243 E:1245 ||| .
Last  ||| S:1245 E:1250 ||| JJ
but  ||| S:1250 E:1254 ||| CC
not  ||| S:1254 E:1258 ||| RB
least ||| S:1258 E:1263 ||| JJS
,  ||| S:1263 E:1265 ||| ,
the  ||| S:1265 E:1269 ||| DT
associated  ||| S:1269 E:1280 ||| JJ
health  ||| S:1280 E:1287 ||| NN
economic  ||| S:1287 E:1296 ||| JJ
burden  ||| S:1296 E:1303 ||| NN
should  ||| S:1303 E:1310 ||| MD
also  ||| S:1310 E:1315 ||| RB
be  ||| S:1315 E:1318 ||| VB
considered ||| S:1318 E:1328 ||| VBN
.  ||| S:1328 E:1330 ||| .
This  ||| S:1330 E:1335 ||| DT
paper  ||| S:1335 E:1341 ||| NN
addresses  ||| S:1341 E:1351 ||| VBZ
some  ||| S:1351 E:1356 ||| DT
issues  ||| S:1356 E:1363 ||| NNS
related  ||| S:1363 E:1371 ||| VBN
to  ||| S:1371 E:1374 ||| TO
the  ||| S:1374 E:1378 ||| DT
use  ||| S:1378 E:1382 ||| NN
of  ||| S:1382 E:1385 ||| IN
cetuximab  ||| S:1385 E:1395 ||| NN
and  ||| S:1395 E:1399 ||| CC
bevacizumab  ||| S:1399 E:1411 ||| NN
in  ||| S:1411 E:1414 ||| IN
advanced  ||| S:1414 E:1423 ||| JJ
NSCLC ||| S:1423 E:1428 ||| NNP
.  ||| S:1428 E:1430 ||| .
The  ||| S:1430 E:1434 ||| DT
main  ||| S:1434 E:1439 ||| JJ
controversial  ||| S:1439 E:1453 ||| JJ
aspects  ||| S:1453 E:1461 ||| NNS
regarding  ||| S:1461 E:1471 ||| VBG
patient  ||| S:1471 E:1479 ||| JJ
selection ||| S:1479 E:1488 ||| NN
,  ||| S:1488 E:1490 ||| ,
the  ||| S:1490 E:1494 ||| DT
real  ||| S:1494 E:1499 ||| JJ
benefit  ||| S:1499 E:1507 ||| NN
of  ||| S:1507 E:1510 ||| IN
therapy ||| S:1510 E:1517 ||| NN
,  ||| S:1517 E:1519 ||| ,
the  ||| S:1519 E:1523 ||| DT
molecular  ||| S:1523 E:1533 ||| JJ
and  ||| S:1533 E:1537 ||| CC
clinical  ||| S:1537 E:1546 ||| JJ
predictors ||| S:1546 E:1556 ||| NN
,  ||| S:1556 E:1558 ||| ,
and  ||| S:1558 E:1562 ||| CC
the  ||| S:1562 E:1566 ||| DT
impact  ||| S:1566 E:1573 ||| NN
of  ||| S:1573 E:1576 ||| IN
other  ||| S:1576 E:1582 ||| JJ
independent  ||| S:1582 E:1594 ||| JJ
variables  ||| S:1594 E:1604 ||| NNS
are  ||| S:1604 E:1608 ||| VBP
carefully  ||| S:1608 E:1618 ||| RB
examined  ||| S:1618 E:1627 ||| VBN
and  ||| S:1627 E:1631 ||| CC
presented ||| S:1631 E:1640 ||| VBN
.  ||| S:1640 E:1642 ||| .
Due  ||| S:1642 E:1646 ||| JJ
to  ||| S:1646 E:1649 ||| TO
many  ||| S:1649 E:1654 ||| JJ
unsolved  ||| S:1654 E:1663 ||| JJ
questions ||| S:1663 E:1672 ||| NNS
,  ||| S:1672 E:1674 ||| ,
no  ||| S:1674 E:1677 ||| DT
definite  ||| S:1677 E:1686 ||| JJ
conclusions  ||| S:1686 E:1698 ||| NNS
can  ||| S:1698 E:1702 ||| MD
be  ||| S:1702 E:1705 ||| VB
supported ||| S:1705 E:1714 ||| VBN
.  ||| S:1714 E:1716 ||| .
The  ||| S:1716 E:1720 ||| DT
final  ||| S:1720 E:1726 ||| JJ
decision  ||| S:1726 E:1735 ||| NN
about  ||| S:1735 E:1741 ||| IN
the  ||| S:1741 E:1745 ||| DT
optimal  ||| S:1745 E:1753 ||| JJ
use  ||| S:1753 E:1757 ||| NN
of  ||| S:1757 E:1760 ||| IN
these  ||| S:1760 E:1766 ||| DT
agents  ||| S:1766 E:1773 ||| NNS
is  ||| S:1773 E:1776 ||| VBZ
left  ||| S:1776 E:1781 ||| VBN
to  ||| S:1781 E:1784 ||| TO
the  ||| S:1784 E:1788 ||| DT
clinical  ||| S:1788 E:1797 ||| JJ
judgment  ||| S:1797 E:1806 ||| NN
of  ||| S:1806 E:1809 ||| IN
each  ||| S:1809 E:1814 ||| DT
treating  ||| S:1814 E:1823 ||| JJ
physician ||| S:1823 E:1832 ||| NN
.  ||| S:1832 E:1834 ||| .
